Let that sink in for a second. The one accessible, cheap, widely distributed safeguard that drug users and outreach workers rely on? It doesn't work on this stuff.

Health officials are sounding the alarm, and they should be. But alarms without action are just noise, and San Francisco has a long, expensive history of making noise on the overdose crisis while the body count keeps climbing.

Here's the uncomfortable truth: the city has poured hundreds of millions into addressing the drug crisis over the past several years. We have supervised consumption debates, needle exchanges, Narcan distribution, street outreach teams, and a constellation of nonprofits collecting public dollars. And yet a single new compound can render a key piece of the harm-reduction infrastructure obsolete overnight. That's not a system — that's a house of cards.

The emergence of novel synthetics isn't surprising. It's the predictable next step in a drug supply chain that adapts faster than government bureaucracies ever will. Illicit manufacturers don't need committee meetings or budget approvals to reformulate. They just do it. Meanwhile, the city's response apparatus moves at the speed of a Board of Supervisors hearing.

What would actually help? For starters, real accountability for the massive sums already being spent. Rapid investment in updated testing technology. And an honest conversation about whether the current strategy — heavy on compassion rhetoric, light on measurable outcomes — is actually saving lives or just managing decline.

No one wants people dying on San Francisco's streets. But wanting something and effectively spending taxpayer money to prevent it are two very different things. This new opioid is a brutal reminder that the crisis isn't static. It evolves. The question is whether San Francisco's leadership can evolve with it — or whether we'll get another round of press conferences, another round of funding requests, and another round of deaths.